Blue Trust Inc. Raises Stock Position in TG Therapeutics, Inc. (NASDAQ:TGTX)

Blue Trust Inc. increased its position in shares of TG Therapeutics, Inc. (NASDAQ:TGTX) by 105.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,121 shares of the biopharmaceutical company’s stock after acquiring an additional 1,605 shares during the quarter. Blue Trust Inc.’s holdings in TG Therapeutics were worth $94,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the company. NBC Securities Inc. increased its holdings in shares of TG Therapeutics by 58.9% during the third quarter. NBC Securities Inc. now owns 1,309 shares of the biopharmaceutical company’s stock valued at $30,000 after acquiring an additional 485 shares in the last quarter. ORG Wealth Partners LLC purchased a new stake in TG Therapeutics during the 3rd quarter worth approximately $53,000. Values First Advisors Inc. acquired a new position in TG Therapeutics during the 3rd quarter valued at approximately $58,000. GAMMA Investing LLC increased its stake in TG Therapeutics by 562.4% during the 4th quarter. GAMMA Investing LLC now owns 2,557 shares of the biopharmaceutical company’s stock valued at $77,000 after purchasing an additional 2,171 shares in the last quarter. Finally, KBC Group NV raised its holdings in shares of TG Therapeutics by 30.5% in the third quarter. KBC Group NV now owns 4,675 shares of the biopharmaceutical company’s stock worth $109,000 after buying an additional 1,092 shares during the last quarter. Hedge funds and other institutional investors own 58.58% of the company’s stock.

Analyst Ratings Changes

Several research firms recently issued reports on TGTX. The Goldman Sachs Group upped their target price on TG Therapeutics from $20.00 to $22.00 and gave the company a “neutral” rating in a research report on Tuesday, November 5th. TD Cowen initiated coverage on TG Therapeutics in a report on Tuesday, October 29th. They issued a “buy” rating and a $50.00 price objective on the stock. JPMorgan Chase & Co. lifted their target price on TG Therapeutics from $30.00 to $43.00 and gave the stock an “overweight” rating in a report on Monday, November 25th. StockNews.com downgraded shares of TG Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, January 31st. Finally, HC Wainwright restated a “buy” rating and set a $55.00 price objective on shares of TG Therapeutics in a research note on Wednesday, January 15th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat.com, TG Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $40.67.

TG Therapeutics Stock Down 1.2 %

TG Therapeutics stock opened at $33.09 on Friday. The business’s 50-day moving average price is $31.44 and its 200 day moving average price is $26.92. The company has a quick ratio of 3.91, a current ratio of 4.59 and a debt-to-equity ratio of 1.27. The firm has a market cap of $5.15 billion, a price-to-earnings ratio of -330.87 and a beta of 2.26. TG Therapeutics, Inc. has a 52 week low of $12.84 and a 52 week high of $36.84.

Insider Activity at TG Therapeutics

In other news, CFO Sean A. Power sold 10,021 shares of the business’s stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $28.53, for a total value of $285,899.13. Following the completion of the sale, the chief financial officer now directly owns 660,611 shares in the company, valued at $18,847,231.83. The trade was a 1.49 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Sagar Lonial sold 5,000 shares of the stock in a transaction that occurred on Monday, November 11th. The shares were sold at an average price of $30.44, for a total value of $152,200.00. Following the transaction, the director now owns 100,195 shares in the company, valued at $3,049,935.80. This trade represents a 4.75 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 26,358 shares of company stock worth $781,497 in the last three months. Company insiders own 10.50% of the company’s stock.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.